Did Bryan Johnson stop all longevity drugs or just rapamycin?

Based on his public statements and published protocol updates, Johnson discontinued rapamycin specifically in 2024. He has continued the broader Blueprint protocol, including acarbose, NMN, testosterone optimization, and other compounds. His protocol undergoes frequent revision based on biomarker data.

Is rapamycin dangerous to stop suddenly?

At the low, pulsed doses used in off-label longevity contexts (typically 3-6 mg weekly), rapamycin discontinuation is not associated with dangerous rebound effects. The mTOR pathway returns to normal signaling within days to weeks. This contrasts with transplant patients on daily immunosuppressive doses, where discontinuation requires careful medical supervision.

Can you replicate Bryan Johnson's protocol safely?

The HealthRX Medical Team advises against replicating any multi-drug protocol without physician oversight. Several compounds in Johnson's stack are prescription medications with real side effects. Others lack adequate human safety data. Johnson himself employs a full-time medical team and undergoes continuous monitoring. The monitoring infrastructure is as important as the drugs themselves.

Do NAD+ levels stay elevated after you stop taking NMN?

No. Clinical data shows NAD+ metabolite levels return to baseline within approximately 2-4 weeks of stopping NMN supplementation. There is no evidence of lasting NAD+ elevation after discontinuation.

Bryan Johnson, Maintenance, and What Happens If You Stop

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

Protocol status: Bryan Johnson publishes his full daily supplement and pharmaceutical regimen through Project Blueprint, making it the single most detailed longevity protocol in the public record.
Confirmed compounds: Rapamycin (discontinued 2024), acarbose, NMN/NAD+ precursors, testosterone, and peptides including BPC-157 and GHK-Cu have all appeared in his published protocol documents.
Key discontinuation event: Johnson publicly stated in 2024 that he stopped rapamycin after his biological-age clocks showed unfavorable movement.
Clinical question this page answers: What does peer-reviewed evidence say about stopping each of these compounds, and what rebound or decay effects should a patient expect?

The Protocol That Made Longevity Pharmacology Public

Bryan Johnson, the tech entrepreneur who sold Braintree Venmo to PayPal for $800 million, began publishing every detail of his daily health regimen in 2021. The protocol, branded Project Blueprint, initially included over 100 daily pills and has expanded to cover pharmaceutical agents, peptides, and biomarker-driven adjustments that Johnson shares in near real-time.

What separates Johnson from other public figures experimenting with longevity compounds is the granularity of his data disclosure. He has published blood panels, organ-specific imaging results, epigenetic clock readings, and cost breakdowns. His "Don't Die" movement and associated media appearances on outlets including Bloomberg and CNBC have turned his self-experimentation into the most visible case study for polypharmacy longevity approaches.

The HealthRX Medical Team considers this public record valuable not because Johnson's protocol should be replicated, but because it raises specific clinical questions about long-term use and discontinuation that are directly relevant to the growing number of patients asking their physicians about these same drugs.

Rapamycin: The Compound He Stopped

Johnson confirmed rapamycin use as part of Blueprint, then publicly discontinued it in 2024. He cited biological-age clock data that moved in the wrong direction, a decision he discussed openly on his YouTube channel and podcast appearances.

Rapamycin (sirolimus) is an mTOR inhibitor originally approved as an immunosuppressant for organ transplant recipients. Its off-label longevity interest stems from consistent lifespan extension in animal models, including the landmark NIA Interventions Testing Program data showing 9-14% lifespan extension in mice.

What happens when you stop rapamycin? In transplant medicine, discontinuation protocols are well-characterized. mTOR inhibition is reversible. After cessation, mTOR signaling returns to baseline within days to weeks depending on dose and duration. The immunosuppressive effects diminish on a similar timeline.

For off-label longevity dosing (typically 3-6 mg weekly, pulsed rather than daily), no controlled human discontinuation studies exist. The theoretical concern is straightforward: any autophagy-enhancing or senolytic-adjacent benefit ceases when the drug stops. There is no known rebound effect in healthy adults, but the metabolic shifts rapamycin induces (including transient insulin resistance and lipid changes documented at higher chronic doses) should normalize after discontinuation.

The HealthRX Medical Team notes that Johnson's decision to stop based on epigenetic clock movement is itself clinically interesting. Biological-age clocks remain imprecise at the individual level, and a single-subject change could reflect noise rather than signal. His willingness to publicly reverse course based on data, even imperfect data, is a reasonable model for how patients should approach experimental protocols.

NAD+ Precursors (NMN): Decay After Discontinuation

Johnson has confirmed NMN (nicotinamide mononucleotide) supplementation as part of his protocol. NMN is a precursor to NAD+, a coenzyme central to cellular energy metabolism and DNA repair pathways.

Human trials of NMN and the related compound NR (nicotinamide riboside) show that NAD+ levels rise during supplementation and return to baseline after cessation. A 2022 clinical trial published in Science demonstrated that NMN supplementation at 250 mg/day increased blood NAD+ metabolites, but the effect was not sustained post-treatment.

Clinical discontinuation profile: NAD+ precursors do not produce withdrawal or rebound. The pharmacology is simple: supply the precursor and NAD+ rises; remove it and levels drift back to their age-determined baseline over approximately 2-4 weeks. The clinical question is whether the benefits accrued during supplementation (if any persist beyond the supplementation window) leave lasting cellular effects. Current evidence does not support lasting benefit after discontinuation.

The HealthRX Medical Team considers NAD+ precursors among the lower-risk compounds in Johnson's stack from a discontinuation standpoint. The more pressing clinical question is whether chronic supplementation at high doses carries any risk of nicotinamide pathway imbalance or methylation burden, a concern that remains unresolved in long-term human data.

Acarbose: A Prescription Drug With Real Discontinuation Data

Acarbose is an alpha-glucosidase inhibitor FDA-approved for type 2 diabetes. Johnson has included it in his published protocol. The longevity rationale comes from the same NIA Interventions Testing Program that flagged rapamycin: acarbose extended lifespan in male mice by 22% (with a smaller effect in females).

Unlike many longevity compounds, acarbose has decades of human safety and discontinuation data from diabetic populations. Stopping acarbose causes postprandial glucose excursions to return to pre-treatment levels. There is no rebound hyperglycemia beyond baseline. The GI side effects (flatulence, bloating, diarrhea) that affect 30-50% of users resolve quickly after discontinuation.

For a non-diabetic individual like Johnson using acarbose to blunt postprandial glucose spikes, stopping simply means glucose handling returns to whatever his metabolic baseline dictates. The HealthRX Medical Team points out that in a healthy individual with normal insulin sensitivity, the magnitude of benefit from acarbose is likely far smaller than in the diabetic mice that generated the longevity signal.

Testosterone and Hormonal Optimization

Johnson has publicly discussed testosterone optimization as part of Blueprint. His protocol targets specific blood levels rather than supraphysiological dosing.

Testosterone replacement or optimization in men carries well-characterized discontinuation effects. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis. Stopping after prolonged use can result in weeks to months of suppressed endogenous production, with symptoms including fatigue, mood changes, decreased libido, and loss of lean mass gains.

The degree of HPG axis suppression depends on dose, duration, and individual physiology. Recovery timelines range from 4 weeks to 12 months. Some men, particularly those who were hypogonadal before treatment, may not fully recover endogenous production.

This is the compound class in Johnson's stack where discontinuation carries the most predictable and clinically significant consequences. The HealthRX Medical Team emphasizes that testosterone is not a supplement you stop without a taper plan and physician oversight. Any patient on long-term testosterone optimization should have a discontinuation protocol discussed before initiation, not after.

Peptides: BPC-157, GHK-Cu, and the Data Gap

Johnson's published protocol has included BPC-157 (a synthetic gastric pentadecapeptide), GHK-Cu (a copper peptide), and hexarelin (a growth hormone secretagogue). These represent the least evidence-supported tier of his stack from a human clinical standpoint.

BPC-157 has extensive preclinical data showing wound healing and anti-inflammatory effects in rodent models. Human trial data remains sparse. There are no controlled studies on discontinuation effects because there are insufficient controlled studies on the effects of use in the first place. GHK-Cu has dermatological and wound-healing data but minimal systemic longevity evidence. Hexarelin, as a GH secretagogue, would be expected to show GH/IGF-1 normalization after cessation.

The HealthRX Medical Team cannot offer evidence-based discontinuation guidance for compounds lacking adequate human efficacy data. The honest clinical answer is: we do not know what stopping BPC-157 does in humans because we do not yet have rigorous data on what starting it does.

The Broader Clinical Question: Polypharmacy Discontinuation

Johnson's protocol is not a single drug. It is a system of 200+ compounds taken simultaneously, adjusted based on biomarker feedback. This creates a clinical scenario with almost no precedent in the medical literature. Polypharmacy in geriatric medicine is well-studied as a risk factor, but polypharmacy as a deliberate longevity strategy in a healthy middle-aged adult lacks any long-term outcome data.

Discontinuing one compound from a 200-agent stack introduces confounding that makes attribution nearly impossible. When Johnson stopped rapamycin and saw clock changes, was that signal from rapamycin removal, from interaction effects shifting across the remaining stack, or from biological noise? The data resolution to answer that question does not exist yet.

The HealthRX Medical Team's clinical position: Johnson's transparency is valuable to the field. His data, while n=1 and uncontrolled, generates hypotheses. But patients should understand that "Bryan Johnson takes it" is not a clinical indication. Each compound in his stack carries its own risk-benefit profile, its own discontinuation characteristics, and its own evidence base (or lack thereof). The decision to start or stop any pharmaceutical agent should be made with a physician who understands the specific compound, not by replicating a public figure's protocol.

Frequently asked questions

›